Herpes virus infections in patients with neoplastic disease. Diagnosis and therapy.
Herpes viruses are among the most common and troublesome opportunistic pathogens infecting patients with neoplastic diseases. The recent development of partially effective and relatively nontoxic antiviral agents offers promise for the prophylaxis or therapy of these infections in high-risk groups. Vidarabine and acyclovir have shown efficacy in several herpes virus infections and are now licensed in the United States. Alpha interferon may also be useful in the prophylaxis or early therapy of certain herpes virus infections. Newer antiviral agents and combination therapies are under study. Early and rapid diagnosis of such infections is critical to the development of effective therapy.
D000212:Acyclovir / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D000998:Antiviral Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003001:Cloning, Molecular; D003586:Cytomegalovirus Infections / Q000175:diagnosis; D006561:Herpes Simplex / Q000473:pathology; D006562:Herpes Zoster / Q000175:diagnosis; D006566:Herpesviridae Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007244:Infectious Mononucleosis / Q000175:diagnosis; D007372:Interferons / Q000627:therapeutic use; D016030:Kidney Transplantation; D007938:Leukemia / Q000150:complications; D008231:Lymphopenia / Q000150:complications; D009369:Neoplasms / Q000150:complications*; D011658:Pulmonary Fibrosis / Q000209:etiology; D014740:Vidarabine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D000998:Antiviral Agents; C020235:brivudine; D007372:Interferons; D014740:Vidarabine; D001973:Bromodeoxyuridine; D000212:Acyclovir